Autem lands $100K Musella grant to probe RF-EMF glioblastoma therapy
What's the deal? Autem Therapeutics has received a $100,000 venture philanthropy grant from The Musella Foundation for Brain Tumor Research & Information to fund research on its glioblastoma device. The grant supports preclinical and early clinical work on AutEMsys, a non-invasive radiofrequency electromagnetic field (RF-EMF) device.
What's the endgame? The Hanover, New Hampshire-based company is developing AutEMsys as a non-invasive, non-toxic treatment for glioblastoma, the most common and aggressive primary brain cancer in adults. Median survival remains roughly 12 to 18 months despite surgery, radiation, and chemotherapy.
What's the research? The money will fund study of RF-EMF exposure in patient-derived "tumoroids" — three-dimensional models grown from patient tumor tissue — and early clinical research in newly diagnosed patients. The work aims to test whether RF-EMF can shift the electrical balance of tumor-infiltrated brain tissue to suppress growth.
Why the grant? Because Autem is a for-profit company, the foundation awarded the money through its venture philanthropy model, which lets it back research beyond traditional nonprofit grant-making. "We're proud to help get this science off the ground and one step closer to brain cancer patients," said Al Musella, founder and president of the Musella Foundation.
By the numbers: Autem last raised a $10 million Series A in June 2022, led by Zentynel Frontier InvestmentsDealroom has a profile for this one. Try Dealroom →. The device is not approved or cleared by the US Food and Drug Administration for any indication.
The signal: The award is modest next to recent sector financings — UP OncolyticsDealroom has a profile for this one. Try Dealroom → drew $2.5 million in NIHDealroom has a profile for this one. Try Dealroom → funding in October for a preclinical therapy — so it reads as targeted research support, not a major round or clinical milestone. Its significance will hinge on whether the work yields credible evidence of biological activity and a path to rigorous testing.
Read more: virtualtrials.org, autemtherapeutics.com
Image credit: Generated with Gemini
